Benchmark Capital downgrades Myriad Genetics (Nasdaq: MYGN) to Hold from Buy.

Benchmark analyst says, "The Company indicated on the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE